Table 2.
PU.1, BSAP, and Oct-2 Expression in Non-Hodgkin’s Lymphoma
| Diagnosis | PU.1 (%) | BSAP (%) | Oct-2 (%) |
|---|---|---|---|
| B-NHL | 29/43 (67) | 21/22 (95) | 32/36 (89) |
| CLL/SLL* | 6/6 (100) | 2/2 (100) | 3/3 (100) |
| FL | 7/7 (100) | 2/2 (100) | 4/4 (100) |
| MCL | 2/3 (67) | 2/2 (100) | 4/6 (67) |
| MZL | 3/3 (100) | 2/2 (100) | 2/2 (100) |
| DLBCL† | 11/18 (61) | 9/10 (90) | 15/17 (88) |
| TCRBCL | 0/6 (0) | 4/4 (100) | 4/4 (100) |
| PTCL | 0/17 (0) | 0/17 (0) | |
| ALCL | 0/7 (0) | 0/7 (0) |
B-NHL, B-cell non-Hodgkin’s lymphoma; CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, extranodal marginal zone lymphoma of MALT type; DLBCL, diffuse large B-cell lymphoma; TCRBCL, T-cell-rich B-cell lymphoma; PTCL, peripheral T-cell lymphoma; ALCL, anaplastic large cell lymphoma.
*Including one case of lymphoplasmacytic lymphoma.
†Excluding TCRBCL.